Lomitapide - Novelion Therapeutics

Drug Profile

Lomitapide - Novelion Therapeutics

Alternative Names: AEGR-733; BMS-201038; Juxtapid; Lojuxta

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Aegerion Pharmaceuticals; Amryt Pharma; Novelion Therapeutics; University of Pennsylvania
  • Class Antihyperlipidaemics; Benzamides; Biphenyl compounds; Fluorenes; Piperidines; Small molecules
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type IIa

Most Recent Events

  • 01 Aug 2018 Preregistration for Hyperlipoproteinaemia type IIa (Adjunctive treatment) in Brazil (PO)
  • 24 Jun 2018 Biomarkers information updated
  • 17 May 2018 Lomitapide - Novelion Therapeutics is available for licensing in Commonwealth of Independent States, Russia, Albania, Bosnia-Herzegovina, Macedonia, Montenegro, Serbia, Kosovo as of 10 May 2018. www.amrytpharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top